Pain Therapeutics Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2013. For the period, the company’s total revenue was $1,958,000 against $2,973,000 a year ago. Operating loss was $443,000 against $148,000 a year ago. Net loss was $408,000 or $0.01 basic and diluted per share against income of $30,000 a year ago.

Pain Therapeutics Inc., Annual General Meeting, May 16, 2013., at 10:00 Central Standard Time. Location: 7801 N Capital of Texas Highway. Agenda: To elect Nadav Friedmann, Ph.D., M.D. and Michael J. O’Donnell as Class I Directors to serve for three-year terms and until their successors are duly elected and qualified; to ratify the selection of Ernst & Young LLP as the independent registered public accounting firm for the company for the fiscal year ending December 31, 2013; to approve, by a non-binding advisory vote, the 2012 executive compensation for the company’s executive officers; and to transact such other business as may properly be brought before the meeting and any adjournments thereof.

On February 11, 2013, the Board of Directors of Pain Therapeutics Inc. appointed Saira Ramasastry to the company’s Board as a Class II director, effective February 11, 2013. The Board also appointed Ms. Ramasastry to the Audit Committee of the Board. In connection with this appointment, the Board determined that Ms. Ramasastry met the qualification requirements for Audit Committee service under NASDAQ Stock Market LLC rules, including determining that she is an independent director under Rule 5605(a)(2) of the Rules and under Rule 10A-3 under the Exchange Act of 1934, as amended. The company amended Article II, Section 1 of the Amended and Restated Bylaws of the company to increase the authorized number of directors constituting the Board to seven.